Understand the source comparison
VIP Neuroprotection Results Timeline: Research Model Comparison
Traumatic Brain Injury (Rodent) 40–60% reduction in TNF-α, IL-1β within 48 hours; reduced lesion volume at 7 days BDNF expression increased 25–35% by week 2; NGF elevated 20% by week 3 Axonal sprouting evident at 8 weeks; synaptic density +30% vs control at 12
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Traumatic Brain Injury (Rodent)
- 40–60% reduction in TNF-α, IL-1β within 48 hours; reduced lesion volume at 7 days
- BDNF expression increased 25–35% by week 2; NGF elevated 20% by week 3
- Axonal sprouting evident at 8 weeks; synaptic density +30% vs control at 12 weeks
- Strong acute effect, moderate long-term structural benefit. Requires sustained dosing beyond 8 weeks
- Neurodegenerative Disease (Alzheimer's Model)
- Microglial M1→M2 shift within 72 hours; reduced Aβ plaque-associated inflammation
- Modest BDNF increase (15–20%) by week 4; variable NGF response
- Dendritic spine density +15–20% at 16 weeks; inconsistent cognitive improvement
- Anti-inflammatory effects clear; structural repair partial. Best as adjunct therapy
- Stroke/Ischemic Injury
- Infarct size reduced 20–30% when administered within 6 hours; oxidative stress markers down 40%
- VEGF and BDNF both elevated 30–40% by week 2
- Angiogenesis increased, functional motor recovery +25% at 8 weeks vs control
- Excellent acute neuroprotection if dosed early; long-term recovery dependent on rehabilitation
- Peripheral Neuropathy
- Pain scores reduced 30–40% within 5–7 days; reduced inflammatory infiltrate
- NGF and GDNF both elevated 35–50% by week 3–4
- Nerve conduction velocity improved 15–25% at 12 weeks; partial remyelination
- Strong acute symptom relief; structural nerve repair requires 12+ weeks